Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEP-363856 in schizophrenia
NCT04115319Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Nov 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of ulotaront in schizophrenia (2 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Adverse Events at 53 weeks, Serious Adverse Events at 53 weeks and 1 more. Started Nov 2019; status: completed.
02
Drugs
ulotaront
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04115319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04115319.